Client 1st Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.05M Buy
1,705
+107
+7% +$109K 0.53% 33
2026
Q1
$1.47M Sell
1,598
-14
-0.9% -$14.2K 0.45% 31
2025
Q4
$1.73M Buy
1,612
+31
+2% +$29.6K 0.54% 30
2025
Q3
$1.21M Hold
1,581
0.4% 38
2025
Q2
$1.23M Hold
1,581
0.45% 35
2025
Q1
$1.31M Buy
1,581
+5
+0.3% +$4.16K 0.51% 27
2024
Q4
$1.22M Hold
1,576
0.47% 32
2024
Q3
$1.4M Buy
+1,576
New +$1.42M 0.55% 27

Other funds holding LLY

Client 1st Advisory Group's LLY Position: Q2 2026 in Review

Client 1st Advisory Group increased its Eli Lilly (LLY) stake by 6.7% in Q2 2026, buying an estimated $109K and bringing the position to 1,705 shares worth $2.05M. The position accounts for 0.53% of the portfolio, ranked #33.

Client 1st Advisory Group first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 1,000 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Client 1st Advisory Group held 1,705 shares of Eli Lilly worth $2.05M as of Q2 2026.
  • Client 1st Advisory Group bought 107 Eli Lilly shares in Q2 2026, an estimated $109K.
  • Eli Lilly made up 0.53% of Client 1st Advisory Group's portfolio in Q2 2026, its #33 holding.
  • Client 1st Advisory Group first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 1,000 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Client 1st Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.